Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
The Minister for Asia and the Middle East (Amanda Milling)
It is a pleasure, as always, to serve under your chairmanship, Mr Hollobone. I am grateful to the right hon. Member for Hayes and Harlington (John McDonnell) for securing this debate and to all hon. Members who have contributed. I will try to respond to some of the right hon. Gentleman’s points.
According to recent research by Imperial College London, the global roll-out of covid vaccines has averted up to 20 million deaths, but progress has been uneven. Hon. Members are absolutely right to want the global roll-out to go further and faster, because too many people remain unvaccinated, particularly in lower income countries and marginalised communities and among those in the grip of humanitarian crises.
The Government’s priority is to end the acute phase of the pandemic by ensuring that those most at risk are fully vaccinated and enabling societies to live with covid. Everyone in this House and throughout the country can be proud of the role the UK has played in developing and rolling out covid vaccinations. UK scientific excellence and co-operation has made a huge contribution to collective knowledge about the virus, including how to treat it and vaccinate against it. Professor Dame Sarah Gilbert and her team created and developed the game-changing Oxford-AstraZeneca vaccine, backed by the UK Government. The Government also backed research into several other successful vaccines that were produced at unprecedented speed, including through our £250 million support to the Coalition for Epidemic Preparedness Innovations, otherwise known as CEPI.
We have also played a big role in the global vaccine roll-out, which has been the fastest ever against a single disease. Furthermore, we are a founder and one of the largest donors to COVAX, with our commitment of £548 million to its advance market commitment. That has helped COVAX to deliver more than 1.5 billion vaccine doses to 146 countries and territories worldwide, including 87 low and middle-income countries.
To help to address the supply shortages last year, we used our presidency of the G7 to make a collective commitment to provide 870 million doses to poorer countries by the end of 2022. Collectively, the G7 has exceeded that commitment by making more than 1 billion doses available. Nationally, we have donated more than 85 million doses to nearly 40 countries and made a further 15 million available. We have done all we can to meet our commitment to share 100 million doses. In 2021, the UK donated 30.8 million doses of the AstraZeneca vaccine, all of which were charged at cost. The OECD Development Assistance Committee will issue guidelines on the reporting of vaccine donations in 2022 later this year.
Through this immense collaborative effort, the world now has enough vaccine supply to enable countries to meet their immunisation goals; indeed, global vaccine supply now far outstrips demand. The key challenge is ensuring that developing countries can effectively administer the vaccines they have. We are working with the covid-19 vaccine delivery partnership and other international partners to tackle delivery bottlenecks and improve vaccine uptake to ensure that covid-19 vaccines reach the most vulnerable. Since January, the vaccine delivery partnership has accelerated progress towards national vaccination targets in more than half of the 34 countries with the lowest vaccination rates, with a strong focus on priority groups.
Community confidence and easy access are critical to successful roll-outs. We are using our development budget to encourage uptake and improve delivery. For example, our Nigeria health programme is supporting delivery and using evidence to build vaccine confidence in five of the poorest states. We have also provided £20 million to the Hygiene and Behaviour Change Coalition, which builds vaccine confidence through community engagement, working with health workers, religious leaders and other influential and trusted voices.
Just as the UK’s scientists and Government made a huge contribution to the first wave of vaccines, we are now working with partners such as COVAX and CEPI to ensure affordable and effective second-generation vaccines and make them available to low and middle-income countries, so that the world can respond rapidly to any new variant of concern. As part of this work, CEPI is supporting the Cambridge-based company DIOSynVax to develop a new pan-coronavirus vaccine to offer broader protection.
This year, we hosted the global pandemic preparedness summit, which raised more than £1.2 billion for CEPI’s work, including a UK Government pledge of £160 million. That money will fund the development of vaccines against new health threats—including possible new covid variants—in 100 days from any outbreak.
Rolling out covid vaccines puts huge pressure on weak and overstretched systems, so we are working with COVAX, the WHO, UNICEF and other partners to support countries in developing sustainable approaches to managing covid and other diseases. For the long-term control of the virus, it is critical to integrate covid-19 vaccination tests and treatments into primary healthcare systems, supported by strong and resilient health systems. The UK Government use our development budget to support countries to strengthen their health systems and work towards universal health coverage. We are also a leading supporter of Gavi’s work on restoring and strengthening immunisation and health systems for the 2.7 million children in the poorest countries who missed out on vaccinations in 2020 because the pandemic prevented them from getting their jabs.
Covid-19 has caused more than 6.3 million reported deaths, and the WHO estimates that there have been up to 15 million excess deaths in total around the world. It has had hard, far-reaching economic, social and health consequences, so stopping the next potential pandemic is vital. That will require a concerted and co-ordinated international effort. In addition to our investment in CEPI, the UK Government have pledged £25 million to a new World Bank-hosted fund for pandemic prevention, preparedness and response. That will help to ensure more equitable access to vaccines, tests and treatments when a future threat to global health emerges.
On TRIPS, the UK Government continue to recognise the importance of the intellectual property system in incentivising innovation, research and the development of new medicines, vaccines and medical technologies. We welcome the consensus-based outcome on the TRIPS agreement reached at the WTO ministerial conference. We believe that decision will make it easier for developed countries to choose to export life-saving covid vaccines while preserving the incentive that intellectual property rights provide to invest in innovation.
John McDonnell
The Minister will soon run out of time, so will she address the issue of support for the WHO’s strategy of rolling out hubs? Will the Government think again?
Amanda Milling
I am grateful to the right hon. Gentleman for putting his case forward, but I have been clear about the UK’s position.
The global vaccine roll-out is pivotal to ending the acute phase of the pandemic and transitioning to living with covid. The points that have been made about delivery and distribution are live issues, and we are working hard with our international partners to resolve them. The Government are also investing in the development of second-generation vaccines, pandemic preparedness and the strengthening of global health systems. That comprehensive approach is the only way to strengthen global resilience to covid and other future health threats.
Question put and agreed to.
Resolved,
That this House has considered disparities in the global distribution of vaccines.